furmonertinib + bevacizumab

Furmonertinib + bevacizumab is a combination therapy under clinical investigation for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations. Furmonertinib is a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that targets both EGFR-sensitive and resistant mutations, including G719X, 19 del, 21 L858R, L861Q, and T790M. It demonstrates high selectivity for mutant EGFR and has enhanced central nervous system penetration due to its unique trifluoroethoxypyridine structure[4][6]. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis in tumors. The combination aims to leverage the targeted inhibition of tumor cell proliferation by furmonertinib with the antiangiogenic effects of bevacizumab to improve outcomes in patients with advanced or metastatic NSCLC harboring EGFR mutations[2][7][9]. This regimen is being evaluated as neoadjuvant therapy before surgery as well as in advanced disease settings.

Brand names

Ivesa

Other names

alflutinib mesylatefurmonertinib mesylatefirmonertinib mesilate